The UK has commenced human trials for an Ebola vaccine developed by scientists at the University of Oxford, following regulatory approval. The vaccine, initiated on May 17, 2026, aims to combat the ongoing Ebola outbreak in the Democratic Republic of the Congo (DRC), which has resulted in 625 deaths and 1,792 confirmed cases.
Details of the Ebola Vaccine Trials
Researchers are currently recruiting volunteers for the initial phase of trials, expected to begin within weeks. Dr. Katrina Pollock, the chief investigator, stated, "We're doing phase one trials of new vaccines all of the time, precisely to be ready for exactly this kind of outbreak." The trial will involve 50 healthy adults aged between 18 and 55.
The vaccine is the first of four being developed specifically for the Bundibugyo species of Ebola, which poses unique challenges due to its high mortality rate. The ongoing outbreak is exacerbated by the conflict zone conditions in the DRC, making the development of a vaccine critical.
Innovative Technology Behind the Vaccine Development
The rapid development of the vaccine is attributed to the technology used in the Oxford/AstraZeneca COVID-19 vaccine. This method employs a genetically modified common cold virus that infects chimpanzees, delivering a snippet of genetic code from the Bundibugyo Ebola virus to provoke an immune response without causing infection. The goal is to prepare the immune system to recognize and fight the virus effectively.
- Vaccine trials will monitor volunteers for a year.
- 620,000 doses have already been manufactured by the Serum Institute of India.
- Previous Ebola outbreaks have been challenging due to the need for separate treatments for different species.
Safety and Efficacy Considerations
While the vaccine shows promise, safety remains a priority. Pollock emphasized that severe side effects are rare, stating, "We thought very deeply about the implications for trials on healthy people." The team is committed to ensuring that all risks are communicated clearly to participants.
Previous vaccines, such as the Oxford COVID-19 vaccine, were credited with saving millions of lives, but they also faced scrutiny for potential side effects. The new Ebola vaccine is designed to minimize risks while addressing an urgent public health need.
🤖 This article was rewritten by Feed and Figures' editorial AI from a report originally published by BBC News. Facts and quotes are preserved from the original; the rewrite focuses on clarity and structure. For the unedited original, see the source link below.
